Benitec Biopharma Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Benitec Biopharma's estimated annual revenue is currently $3.1M per year.(i)
  • Benitec Biopharma's estimated revenue per employee is $182,353

Employee Data

  • Benitec Biopharma has 17 Employees.(i)
  • Benitec Biopharma grew their employee count by 6% last year.

Benitec Biopharma's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Operating OfficerReveal Email/Phone
3
SVP ManufacturingReveal Email/Phone
4
Executive DirectorReveal Email/Phone
5
Scientist IReveal Email/Phone
6
Senior ScientistReveal Email/Phone
7
Senior Research Associate IIReveal Email/Phone
8
Senior Research Associate IReveal Email/Phone
9
Senior ScientistReveal Email/Phone
10
ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M50%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M4-50%N/AN/A
#6
$0.7M80%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1731%N/AN/A
Add Company

What Is Benitec Biopharma?

Benitec is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference (RNAi) with gene therapy with a goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration. Benitec is using its technology, called DNA-directed RNA interference (ddRNAi) to develop a pipeline of product candidates for the treatment of several chronic and life-threatening human diseases , including oculopharyngeal muscular dystrophy (OPMD) and hepatitis B. By combining the specificity and gene silencing effect of RNAi with gene therapy, ddRNAi has the potential to produce long-lasting silencing of disease-causing genes from a single administration, which could minimize the requirement for patients to take regular doses of medicine. Benitec’s objective is to become the leader in discovering, developing, clinically validating and commercializing ddRNAi-based therapeutics for a range of human diseases with high unmet clinical need or large patient populations and, as a result, provide a better life for patients with these diseases.

keywords:N/A

N/A

Total Funding

17

Number of Employees

$3.1M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1M17-23%N/A
#2
N/A1721%N/A
#3
$1.6M18-5%N/A
#4
$2M18-5%N/A
#5
$2.8M1820%N/A